ADME pathway approach for pharmacogenetic studies of anti-HIV therapy

Détails

ID Serval
serval:BIB_69D5CFDAB718
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
ADME pathway approach for pharmacogenetic studies of anti-HIV therapy
Périodique
Pharmacogenomics
Auteur(s)
Lubomirov  R., Csajka  C., Telenti  A.
ISSN
1462-2416 (Print)
Statut éditorial
Publié
Date de publication
06/2007
Volume
8
Numéro
6
Pages
623-633
Notes
Journal article --- Old month value: Jun
Résumé
Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multidrug therapies that are prescribed for long periods. However, there has been limited success with the current approach where one or few candidate genes are examined for a limited number of allelic variants. A change in paradigm emerges from the availability of the HapMap, the wealth of data on less common genetic polymorphisms, and new genotyping technology. We present a comprehensive review of functional and putative functional variants in genes encoding absorption, distribution, metabolism and excretion (ADME) proteins relevant to HIV therapy. We propose an analytical array based on our review of the literature, web resources and use of bioinformatic analysis. We identified 126 genes with proven or potential role in HIV therapy. Variation in these genes can be characterized by 2428 SNPs (in Caucasians). On average, a gene is covered by 20 SNPs. This review compiles information for future analysis of the role of specific genes/variants in the exposure and response to antiretroviral therapy to generate a ranked list of new genetic variants for future studies.
Pubmed
Web of science
Création de la notice
25/01/2008 10:48
Dernière modification de la notice
20/08/2019 14:24
Données d'usage